Form 4: IGM Biosciences CFO Acquires Restricted Stock Units

IGM Biosciences' Chief Financial Officer, Misbah Tahir, acquired 66,667 restricted stock units (RSUs) on November 18, 2024.

Summary

• Misbah Tahir, the Chief Financial Officer of IGM Biosciences, acquired 66,667 restricted stock units (RSUs) on November 18, 2024.
• These RSUs were granted at a price of $0.
• The RSUs represent a contingent right to receive one share of IGM Biosciences' common stock per unit.
• 50% of the RSUs will vest on January 12, 2026, and the remaining 50% will vest on January 11, 2027, provided Mr. Tahir remains a service provider through each vesting date.
• Following this transaction, Mr. Tahir beneficially owns a total of 189,361 shares of common stock.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction of stock-based compensation, which is generally viewed positively as it aligns management's interests with shareholders. There are no indications of any negative issues.

Positives

• The grant of RSUs to the CFO aligns his interests with the long-term success of the company.
• The vesting schedule encourages continued service and commitment from the CFO.

Future Outlook

The vesting of the RSUs is contingent on the CFO's continued service with the company.

Industry Context

The granting of stock-based compensation is a common practice in the biotechnology industry to attract and retain key executives.

Comparison to Industry Standards

• Stock-based compensation, such as RSUs, is a standard practice for executive compensation in the biotech industry.
• Vesting schedules are typically used to ensure long-term commitment from executives.
• The specific vesting terms (50% in two tranches) are within the typical range for such grants.

Stakeholder Impact

• The RSU grant aligns the CFO's interests with those of shareholders, potentially leading to increased focus on long-term value creation.
• The vesting schedule encourages the CFO's continued service, which is beneficial for the company's stability.

Key Dates

Keywords

IGM Biosciences, Restricted Stock Units, RSUs, Misbah Tahir, CFO, Beneficial Ownership, Equity Compensation, Vesting